Recent News

• 12.05.2025 - Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
• 12.05.2025 - Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
• 12.04.2025 - Capricor Therapeutics Announces Proposed Public Offering of Common Stock
• 12.04.2025 - Capricor Therapeutics Announces Proposed Public Offering of Common Stock
• 12.03.2025 - Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
• 11.24.2025 - Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
• 11.10.2025 - Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.03.2025 - Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Recent Filings

• 12.05.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.05.2025 - 8-K Current report
• 12.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.05.2025 - EX-99.1 EX-99.1
• 12.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.03.2025 - 8-K Current report
• 12.03.2025 - 8-K Current report
• 12.03.2025 - EX-99.1 EX-99.1
• 12.03.2025 - EX-99.1 EX-99.1
• 11.10.2025 - EX-99.1 EX-99.1